Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
复制标题
DOI：
10.1200/jco.2006.08.3089
复制
发表时间：
2007-03-01
影响因子：
45.3
通讯作者：
Byrd, John C.
中科院分区：
文献类型：
--
作者：
Grever, Michael R.;Lucas, David M.;Byrd, John C.
目的基因组特征包括未突变的免疫球蛋白可变区重链（IgV（H））基因、del（11q22.3）、del（17p13.1）和p53突变已被报道可预测慢性淋巴细胞白血病（CLL）患者的临床病程和总生存期。此外，ZAP-70和Bcl-2家族蛋白已被探索作为预测outcome.Patients和MethodsWe前瞻性评估的预后意义的一个全面的面板的实验室因素对两个反应和无进展生存期（PFS）使用的样本和数据从235例患者登记到一个治疗试验。患者接受氟达拉滨（FL; n = 113）或氟达拉滨加环磷酰胺（FC; n = 122）作为美国组间随机试验的一部分，以前未经治疗的CLL patient.ResultsComplete response（CB）率为24.6%的患者接受FC和5.3%的患者接受FL（P =.00004）。接受FC治疗的患者的PFS在统计学上显著延长（接受FC治疗的患者的中位PFS为33.5个月，接受FL治疗的患者为19.9个月，P
PurposeGenomic features including unmutated immunoglobulin variable region heavy chain (IgV(H)) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome.Patients and MethodsWe prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients.ResultsComplete response (CB) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P =.00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL, P